Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 10, 2024

SELL
$47.98 - $54.4 $1,631 - $1,849
-34 Reduced 0.59%
5,687 $308,000
Q4 2023

Jan 11, 2024

SELL
$48.48 - $57.85 $95,748 - $114,253
-1,975 Reduced 25.66%
5,721 $294,000
Q3 2023

Oct 27, 2023

BUY
$57.89 - $64.73 $445,521 - $498,162
7,696 New
7,696 $447,000
Q1 2023

Apr 13, 2023

SELL
$65.71 - $74.53 $49,742 - $56,419
-757 Reduced 8.49%
8,156 $565,000
Q4 2022

Jan 09, 2023

BUY
$68.48 - $81.09 $136 - $162
2 Added 0.02%
8,913 $641,000
Q3 2022

Oct 11, 2022

SELL
$0.13 - $76.84 $81 - $48,409
-630 Reduced 6.6%
8,911 $633,000
Q2 2022

Jul 11, 2022

BUY
$72.62 - $79.98 $24,981 - $27,513
344 Added 3.74%
9,541 $735,000
Q1 2022

Apr 26, 2022

SELL
$61.48 - $73.72 $12,664 - $15,186
-206 Reduced 2.19%
9,197 $672,000
Q4 2021

Jan 21, 2022

BUY
$53.63 - $62.52 $504,282 - $587,875
9,403 New
9,403 $586,000
Q3 2021

Nov 10, 2021

SELL
$59.17 - $69.31 $916,188 - $1.07 Million
-15,484 Closed
0 $0
Q2 2021

Jul 21, 2021

SELL
$61.91 - $67.42 $473,054 - $515,156
-7,641 Reduced 33.04%
15,484 $1.04 Million
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $1.37 Million - $1.54 Million
23,118 Added 330257.12%
23,125 $1.46 Million
Q1 2021

May 06, 2021

SELL
$59.34 - $66.74 $1.55 Million - $1.75 Million
-26,175 Reduced 99.97%
7 $8,000
Q4 2020

Jan 21, 2021

SELL
$57.74 - $65.43 $35,394 - $40,108
-613 Reduced 2.29%
26,182 $1.62 Million
Q3 2020

Oct 30, 2020

SELL
$57.43 - $63.64 $151,155 - $167,500
-2,632 Reduced 8.94%
26,795 $1.62 Million
Q2 2020

Jul 23, 2020

BUY
$54.82 - $64.09 $1.61 Million - $1.89 Million
29,427 New
29,427 $1.73 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Grandview Asset Management LLC Portfolio

Follow Grandview Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandview Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandview Asset Management LLC with notifications on news.